Minimally Invasive Right Colectomy Anastomosis Study

Overview

Right colectomy (hemicolectomy) involves the removal of the cecum, the ascending colon, the hepatic flexure, the first one-third of the transverse colon, part of the terminal ileum, and the associated regional fat and lymph nodes, and is the accepted treatment for malignant neoplasms of the right colon.

A minimally invasive approach is commonly used for right colectomy, with studies reporting reduced complications, less blood loss, and hospital stay when compared to an open approach.

However, there remains controversy regarding whether robotic assistance is advantageous for this technique and whether an intracorporeal (ICA) or extracorporeal anastomosis (ECA) is best.

MIRCAST is a prospective, observational, international, multi-center, 4-parallel-cohorts study. Sites or surgeons will select a cohort of the study for which they are qualified. Four cohorts will be the subject of study:

1. Robotic Right Colectomy with ICA

2. Robotic Right Colectomy with ECA

3. Laparoscopic Right Colectomy with ICA

4. Laparoscopic Right Colectomy with ECA

All patient assessments will be done according to the sites standard of care. Parameters routinely recorded during right colectomy surgery will be collected prospectively. Enrolled subjects will undergo assessments at the following intervals: pre-operative, operative, discharge, 30 days, 3 months, 1 year and 2 years post-surgery.

Full Title of Study: “A Prospective Observational Multi-center 4 Cohort Study Comparing Robotic Assisted and Laparoscopic Invasive Right Colectomy and Intracorporeal Anastomosis Versus Extracorporeal Anastomosis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 1, 2021

Detailed Description

MIRCAST study is an observational, prospective, parallel cohorts, international, multi-center to compare robotic assisted and laparoscopic minimally invasive right colectomy, and intracorporeal anastomosis versus extracorporeal anastomosis.

The research is coordinated by Marcos Gómez Ruiz MD PhD from Hospital Universitario Marqués de Valdecilla in Santander, Spain; the sponsorship is performed by Fundacion Instituto de Investigación Marqués de Valdecilla (IDIVAL). The European Society of Coloproctology (ESCP) endorses MIRCAST Study and will run a quality audit/independent monitoring of the study.

The objectives of study are to compare of the peri-operative complications after robotic assisted and laparoscopic minimally invasive right colectomy with intracorporeal anastomosis versus extracorporeal anastomosis.

To Identify potential benefits of robotic assisted procedures for right colon resections.

Interventions

  • Procedure: Extracorporeal Anastomosis
    • Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
  • Procedure: Intracorporeal Anastomosis
    • Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
  • Procedure: Robotic Surgery
    • Procedure is performed using robotic instruments
  • Procedure: Laparoscopic Surgery
    • Procedure is performed using standard laparoscopic instruments

Arms, Groups and Cohorts

  • Robotic Right Colectomy with ICA
    • Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques. Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction.
  • Robotic Right Colectomy with ECA
    • Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques. Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
  • Laparoscopic Right Colectomy with ICA
    • Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body. Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction.
  • Laparoscopic Right Colectomy with ECA
    • Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body. Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.

Clinical Trial Outcome Measures

Primary Measures

  • Surgical wound infection
    • Time Frame: 30 days
    • (CDC definition [Health Protection Agency. Surveillance of Surgical Site Infection in England: October 1997-September 2005. London: Health Protection Agency; 2006): Superficial incisional, affecting the skin and subcutaneous tissue. These infections may be indicated by localised (Celsian) signs such as redness, pain, heat or swelling at the site of the incision or by the drainage of pus.
  • Clavien Dindo Complication
    • Time Frame: 30 days
    • Complications according to Clavien Dindo Classification.

Secondary Measures

  • Overall Survival
    • Time Frame: 2 years
    • The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive
  • Disease Free Survival (DFS)
    • Time Frame: 2 years
    • Length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
  • Local Recurrence rate
    • Time Frame: 2 years
    • Rate of cancer that has recurred at or near the same place as the original (primary) tumor
  • Distant metastases rate
    • Time Frame: 2 years
    • Rate of Cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes
  • Rate of Unplanned Conversions to open surgery
    • Time Frame: 7 days
    • When anything apart of the anastomosis had to be done through the laparotomy. If the anastomosis is not completely performed in an intracorporeal approach, the case is considered also converted
  • Operative time (min)
    • Time Frame: 7 days
    • Operative time from skin to skin in minutes
  • Complete mesocolic excision (CME)
    • Time Frame: 30 days
    • Complete Mesocolic Excision is defined as complete resection of the mesocolon with its anatomical envelope. Anatomical report should include any defect on CME specimen (Hohenberger W, Weber K., Matzel K., Papadopoulost T., Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation – technical notes and outcome. Colorectal Disease 11, 354-365 2008. doi:10.1111/j.1463-1318.2008.01735.x)
  • Number of Harvested Lymph Nodes
    • Time Frame: 30 days
    • Number of harvested Lymph nodes according to the definitive pathological report.
  • R0 Resection
    • Time Frame: 30 days
    • Rate of resection without any affected margins during the surgical procedure.
  • Length of Stay (LOS, days)
    • Time Frame: 3 months
    • In hospital stay of the patient from the day that they are admitted before surgery to the day that they are fit to leave the hospital after the procedure.
  • Ventral hernia (assessed 1& 2 years after the right colectomy)
    • Time Frame: 1 and 2 years after the procedure
    • Incidence of ventral hernia 1 year after the procedure and 2 years after the procedure at the laparotomy site.
  • Quality of Life Questionnaire (QLQ) of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30
    • Time Frame: 3 months and 1 year after the procedure
    • Quality of Life Questionnaire (QLQ) of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Score 3 months and 1 year after the procedure.
  • Quality of Life Questionnaire (QLQ) of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CR29
    • Time Frame: 3 months and 1 year after the procedure
    • Quality of Life Questionnaire (QLQ) of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CR29 Score 3 months and 1 year after the procedure.
  • C-Reactive Protein value (CRP) days 1 & 3 postoperative
    • Time Frame: 1 and 3 postoperative days.
    • CRP values on postoperative day 1 and 3.

Participating in This Clinical Trial

Inclusion Criteria

  • 18 years or older.
  • Right colon tumor with indication for right colectomy (benign or malignant disease)
  • Patient has a life expectancy of at least 12 weeks
  • Patients with adequate performance status (Eastern Cooperative Oncology Group Scale score of ≤2)
  • Patient has signed and dated the Informed consent before patient inclusion in the study

Exclusion Criteria

  • Patient with a comorbid illness or condition that would preclude the use of surgery
  • Patients with cT4b tumors
  • Patients unwilling to comply with all follow-up study requirements
  • Patient undergoing emergency procedures
  • Planned colonic surgery along with major concomitant procedures (e.g. liver resections, other intestinal resections)
  • Metastatic disease
  • Pregnant or suspected pregnancy
  • Inflammatory Bowel Disease (Crohn´s Disease or Ulcerative Colitis)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Instituto de Investigación Marqués de Valdecilla
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marcos Gómez Ruiz, MD PhD, Principal Investigator, Hospital Universitario Marqués de Valdecilla, IDIVAL
    • Galo Peralta, MD, Study Chair, Instituto de Investigación Marqués de Valdecilla
  • Overall Contact(s)
    • Marcos Gómez Ruiz, MD PhD, 0034942202520, marcos.gomez@scsalud.es

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.